Autolus Therapeutics plc (AUTL)

Autolus Therapeutics plc (AUTL) Healthcare & Pipeline Overview

Autolus Therapeutics plc is a London-based clinical-stage biopharmaceutical company focused on developing innovative T-cell immunotherapies for oncological conditions. With a pipeline targeting various cancers like ALL, peripheral T-cell lymphoma, and multiple myeloma, Autolus aims to address significant unmet medical needs through its specialized programmed T-cell technology.

What Is the Investment Thesis for AUTL?

Autolus Therapeutics plc presents an investment thesis centered on its specialized clinical-stage pipeline of T-cell immunotherapies for oncology. The company's lead candidate, AUTO1, in Phase 1b/2 trials for adult ALL, and AUTO1/22 in Phase 1 for pediatric ALL, represent significant potential in areas with high unmet medical need. Further pipeline diversification with AUTO4 for peripheral T-cell lymphoma and AUTO8 for multiple myeloma, both in Phase I, indicates a broad strategic approach to cancer treatment. The company's market capitalization stands at $0.42 billion, reflecting its early-stage nature. While current financials show a profit margin of -312.0% and a gross margin of -11.2%, typical for clinical-stage biotechs, successful clinical trial progression and potential regulatory approvals are key catalysts. The high beta of 2.01 suggests significant volatility, characteristic of the biotechnology sector. Future value drivers include positive data readouts, advancement of programs to later-stage trials, and potential strategic partnerships or licensing agreements that could provide non-dilutive funding and validation.

Based on FMP financials and quantitative analysis

AUTL Key Highlights

• Market capitalization of $435.04M, reflecting its valuation as a clinical-stage biotechnology company focused on T-cell immunotherapies.
• Profit margin of -312.0%, indicative of substantial research and development expenditures typical for companies in the drug development phase without commercialized products.
• Gross margin of -11.2%, consistent with a business model heavily invested in R&D and not yet generating significant product revenue.
• Beta of 2.01, suggesting the stock exhibits higher volatility compared to the broader market, a common characteristic for early-stage biotechnology firms.
• Extensive clinical pipeline including AUTO1 (Phase 1b/2 for adult ALL), AUTO1/22 (Phase 1 for pediatric ALL), AUTO4 (Phase 1 for peripheral T-cell lymphoma), and AUTO8 (Phase I for multiple myeloma), demonstrating active progression in multiple oncology indications.

Who Are AUTL's Competitors?

AUTL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AUTL's Key Strengths?

• Robust clinical pipeline with multiple T-cell immunotherapy candidates targeting various cancers.
• Specialized expertise in programmed T-cell technology, a cutting-edge area of oncology.
• Lead candidates (AUTO1, AUTO1/22) addressing high unmet needs in ALL populations.
• Diversified pipeline extending to peripheral T-cell lymphoma and multiple myeloma.

What Are AUTL's Weaknesses?

• Clinical-stage company with no commercialized products, leading to negative profit and gross margins.
• High reliance on successful outcomes of ongoing and future clinical trials.
• Significant R&D expenses requiring continuous capital investment.
• High beta (2.01) indicates substantial stock price volatility.

What Could Drive AUTL Stock Higher?

• Release of Phase 1b/2 clinical data for obecabtagene autoleucel (AUTO1) in adult acute lymphoblastic leukemia (ALL) during late 2026 or early 2027, which could significantly impact the program's future trajectory and investor sentiment.
• Progression of AUTO1/22 from Phase 1 to Phase 2 trials for pediatric relapsed or refractory ALL, anticipated in late 2026, signaling positive safety and preliminary efficacy.
• Continued enrollment and data collection for AUTO4 in Phase 1 for peripheral T-cell lymphoma and AUTO8 in Phase I for multiple myeloma, with initial data expected in 2027.
• Potential for new strategic partnerships or licensing agreements for pipeline assets, which could provide non-dilutive funding and external validation of its technology platform.

What Are the Key Risks for AUTL?

• Financial-distress signal — its Altman Z-Score of -3.93 sits in the distress zone (elevated bankruptcy risk).
• Clinical trial failures or unexpected adverse events for any of its pipeline candidates, particularly AUTO1, could significantly devalue the company and delay or halt development.
• High cash burn rate associated with extensive research and development activities, necessitating future capital raises that could dilute existing shareholders.
• Intense competition within the T-cell immunotherapy and broader oncology markets, which could limit market penetration or pricing power for any approved therapies.
• Regulatory hurdles and lengthy approval processes inherent in the biotechnology industry, which could delay market entry even with positive clinical data.
• Dependence on third-party manufacturers for cell therapy production, introducing supply chain risks and potential delays in clinical development or commercialization.

What Are the Growth Opportunities for AUTL?

• Growth opportunity 1: Advancement of Obecabtagene Autoleucel (AUTO1) for Adult ALL. AUTO1 is currently in Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Successful progression through these trials, particularly positive data readouts on efficacy and safety, could significantly de-risk the program and attract potential partners or accelerate regulatory pathways. The global market for ALL treatments is projected to reach several billion dollars annually, with a substantial portion dedicated to adult patients, representing a significant commercial opportunity for Autolus if AUTO1 achieves market approval.
• Growth opportunity 2: Development of AUTO1/22 for Pediatric Relapsed/Refractory ALL. This program is in a Phase 1 study, targeting a critical unmet need in pediatric patients with relapsed or refractory ALL. The market for pediatric oncology treatments, while smaller than adult markets, often commands premium pricing due to the severity of the disease and limited treatment options. Positive clinical data and subsequent advancement could position Autolus as a key player in this specialized and high-impact therapeutic area, potentially leading to accelerated regulatory pathways given the orphan designation potential.
• Growth opportunity 3: Progression of AUTO4 for Peripheral T-cell Lymphoma (PTCL). AUTO4, a programmed T cell therapy targeting TRBC1, is in Phase 1 for PTCL. This represents a diversification beyond ALL into another challenging hematological malignancy. The PTCL market, though niche, has a high unmet need for more effective and durable therapies. Successful clinical development of AUTO4 could open up a new revenue stream and demonstrate the versatility of Autolus's T-cell platform, expanding its addressable market and attracting interest from investors and pharmaceutical collaborators.
• Growth opportunity 4: Clinical Development of AUTO8 for Multiple Myeloma. AUTO8 is currently in Phase I clinical trials for multiple myeloma, a plasma cell cancer that remains largely incurable despite recent advancements. The multiple myeloma market is one of the largest and fastest-growing segments within hematologic oncology, valued at tens of billions of dollars globally. Positive early-stage data for AUTO8 could validate Autolus's approach in a highly competitive but lucrative indication, offering substantial long-term growth potential and attracting significant attention from the broader oncology community.
• Growth opportunity 5: Preclinical Advancement of AUTO6NG for Neuroblastoma. AUTO6NG, a programmed T cell therapy targeting GD2 for neuroblastoma, is in preclinical research. While early-stage, successful preclinical development and subsequent IND filing would represent a significant milestone. Neuroblastoma is a rare but aggressive childhood cancer with high unmet needs. Developing a novel T-cell therapy for this indication could provide a valuable asset in Autolus's pipeline, demonstrating its commitment to addressing difficult-to-treat cancers and potentially benefiting from orphan drug incentives and expedited review processes in the future.

What Opportunities Does AUTL Have?

• Positive clinical trial data readouts could significantly increase valuation and attract partnerships.
• Expansion into additional oncology indications or combination therapies.
• Potential for expedited regulatory pathways (e.g., orphan drug designation) for certain indications.
• Strategic collaborations or licensing agreements to fund development and access broader markets.

What Threats Does AUTL Face?

• Clinical trial failures or unexpected adverse events could halt development.
• Intense competition from other biotechnology and pharmaceutical companies developing cancer therapies.
• Regulatory hurdles and lengthy approval processes for novel cell therapies.
• Patent expirations or challenges to intellectual property could erode competitive advantage.

What Are AUTL's Competitive Advantages?

• Proprietary programmed T-cell technology platform, offering potential differentiation in efficacy and safety profiles.
• Extensive clinical pipeline targeting multiple distinct oncological indications, diversifying risk and opportunity.
• Specialized expertise in T-cell immunotherapy development, a complex and high-barrier-to-entry field.
• Intellectual property surrounding its specific T-cell constructs and manufacturing processes.
• Early-mover advantage in specific therapeutic areas or with particular targets within the T-cell therapy space.

What Does AUTL Do?

Autolus Therapeutics plc, established in 2014 and headquartered in London, United Kingdom, is a clinical-stage biopharmaceutical company dedicated to the development of T-cell-based immunotherapies for the treatment of various oncological conditions. The company's strategic focus is on leveraging its proprietary programmed T-cell technology to create highly differentiated and potent therapies. Since its inception, Autolus has rapidly advanced a robust pipeline of investigational programs, moving several candidates into clinical trials. A cornerstone of its pipeline is obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, which is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL), a severe hematological malignancy. Building on this, AUTO1/22 is in a Phase 1 study, specifically designed for pediatric patients experiencing relapsed or refractory ALL, addressing a critical need in this vulnerable population. Beyond ALL, Autolus is diversifying its therapeutic reach with AUTO4, a programmed T cell therapy targeting TRBC1, which is being developed for peripheral T-cell lymphoma. Additionally, AUTO8, another product candidate, is in Phase I clinical trials for multiple myeloma, a plasma cell cancer. In its earlier developmental stages, the company is also exploring AUTO6NG, a programmed T cell therapy in preclinical research targeting GD2 for neuroblastoma, and AUTO5, another hematological product candidate in preclinical development. Autolus Therapeutics employs 647 individuals, reflecting its significant investment in research and development capabilities to bring these innovative therapies to market.

What Products and Services Does AUTL Offer?

• Develops T-cell-based immunotherapies for various cancer types.
• Focuses on programmed T-cell technology to enhance therapeutic efficacy.
• Conducts clinical trials for lead candidate obecabtagene autoleucel (AUTO1) for adult acute lymphoblastic leukemia (ALL).
• Advances AUTO1/22 in Phase 1 for pediatric relapsed or refractory ALL.
• Researches AUTO4, a T-cell therapy targeting TRBC1 for peripheral T-cell lymphoma.
• Explores AUTO8 in Phase I clinical trials for multiple myeloma.
• Engages in preclinical development for AUTO6NG targeting GD2 for neuroblastoma.
• Maintains a pipeline of investigational hematological product candidates, including AUTO5.

How Does AUTL Make Money?

• Primarily focused on research and development (R&D) of novel T-cell immunotherapies.
• Aims to advance product candidates through various phases of clinical trials to demonstrate safety and efficacy.
• Potential future revenue streams from commercialization of approved therapies, either independently or through partnerships.
• May seek licensing agreements or collaborations with larger pharmaceutical companies for funding, development, and commercialization.
• Relies on capital raises and strategic investments to fund extensive R&D activities and clinical operations.

What Industry Does AUTL Operate In?

Autolus Therapeutics plc operates within the highly innovative and competitive biotechnology industry, specifically focusing on the burgeoning field of T-cell-based immunotherapies for oncology. This segment of the healthcare sector is characterized by intense research and development, high capital requirements, and significant regulatory hurdles. The broader market for cancer therapeutics is substantial and growing, driven by an aging global population and advancements in personalized medicine. Autolus positions itself by developing programmed T-cell therapies, a specialized area within cell therapy that aims to enhance efficacy and safety profiles. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms also pursuing cell therapies and other novel oncology treatments. Autolus differentiates itself through its specific targets and proprietary technology, aiming to carve out market share in areas like acute lymphoblastic leukemia and peripheral T-cell lymphoma, where current treatments may have limitations or significant side effects.

Who Are AUTL's Key Customers?

• Future customers will be patients suffering from specific oncological conditions such as acute lymphoblastic leukemia, peripheral T-cell lymphoma, and multiple myeloma.
• Healthcare providers, including oncologists and specialized treatment centers, who prescribe and administer advanced cancer therapies.
• Hospitals and clinics that incorporate innovative cell therapies into their treatment protocols.
• Potentially, pharmaceutical partners seeking to license or co-develop novel oncology treatments.
• Regulatory bodies, through the submission of clinical data for approval of new therapies.

FY2026 estForward Outlook

Wall Street analysts project Autolus Therapeutics plc revenue of about $129.0M for fiscal 2026, with EPS near $-0.87. The estimate reflects 6 contributing analysts.

F-Score 4/9Financial Health

Autolus Therapeutics plc's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.93 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -54.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -74.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -73.3%, the inverse of the P/E and a quick read on earnings relative to price.

Autolus Therapeutics plc (AUTL) Valuation Context

Valued at $435.04M, AUTL is classified as a small-cap stock. Relative to its peer group, AUTL's quantitative score of 44/100 is below the peer average of 76/100.

AUTL Revenue & Earnings Trend

In Q1 2026, AUTL generated $26.2M in top-line revenue, marking a sequential increase of 8.1%. The company recorded a net loss of $71.6M, with diluted EPS of $-0.27. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, AUTL averaged $-0.27 in diluted EPS.

Company Profile

Autolus Therapeutics plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Christian Martin Itin. AUTL has traded publicly since 2018.

AUTL Financials

AUTL Latest News

AUTL Analyst Consensus

AUTL MoonshotScore

AUTL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources